Guided Therapeutics, Inc. (GTHP) Fair Value 2026

GTHP · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-27, Guided Therapeutics, Inc. (GTHP) trades at $0.23. QOC: 5.5/10. Value Trap Risk: 39/100 (LOW). 1/13 models active.

Key Facts

Ticker
GTHP
Price
$0.23
Quality Score
5.5/10
Value Trap Risk
39/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give GTHP?

1 Intrinsic Value Models vs. Current Price ($0.23)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $0.01 -96.2%

All Models Active

All 1 models are displayed above.

What Is Guided Therapeutics, Inc. (GTHP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Guided Therapeutics, Inc.'s intrinsic value is estimated at $0.01, suggesting the stock is overvalued at its current price of $0.24. With 1 out of 1 models flagging downside (-96.2% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About GTHP?

1 of 13 models are currently active for GTHP. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does GTHP Rank in Medical Devices?

Among 157 Medical Devices stocks, GTHP ranks #112 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, Guided Therapeutics, Inc. competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is GTHP a Value Trap?

CirclFi's Value Trap algorithm assigns GTHP a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Guided Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Guided Therapeutics, Inc. is rated at 5.5/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GTHP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GTHP's 1 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Guided Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

LUCDLucid Diagnostics Inc.QOC 5.5INBSIntelligent Bio Solutions Inc.QOC 5.4NXLNexalin Technology, Inc.QOC 5.6QSIQuantum-Si incorporatedQOC 5.4PLSMPulsenmore Ltd.QOC 5.6NUWENuwellis, Inc.QOC 5.3LMRILumexa Imaging Holdings, Inc.QOC 3.5BRKRBruker CorporationQOC 7.5TNDMTandem Diabetes Care, Inc.QOC 6.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: LUCD · INBS · NXL · QSI · PLSM · NUWE · LMRI · BRKR · TNDM · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to GTHP?

7 companies across all industries closest to GTHP’s Quality of Company score of 5.5/10.

LVWRLiveWire Group, Inc.QOC 5.5CLIKClick Holdings LimitedQOC 5.5ZBAOZhibao Technology Inc.QOC 5.5SEEDOrigin Agritech LimitedQOC 5.5PWDYPowerdyne International, Inc.QOC 5.5BOTYLingerie Fighting Championships, Inc.QOC 5.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LVWR · CLIK · ZBAO · SEED · PWDY · BOTY · NVDA

Where Does GTHP Sit in CirclFi's Medical Devices Rankings?

GTHP is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Guided Therapeutics, Inc.’s Valuation?

What is Guided Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Guided Therapeutics, Inc. (GTHP). The Quality of Company score is 5.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GTHP overvalued or undervalued right now?

At $0.23, 0 of 1 active models suggest GTHP may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Guided Therapeutics, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.5 mean for GTHP?

Guided Therapeutics, Inc.'s QOC of 5.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on GTHP?

CirclFi analyzes GTHP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is GTHP a value trap in 2026?

Guided Therapeutics, Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Guided Therapeutics, Inc. (GTHP) a Quality of Company score of 5.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/GTHP/ · Methodology
Primary sources for this GTHP valuation
  • Financial statements: Guided Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000924515) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GTHP as of ; valuations recomputed .